

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Berge Terence M</u> <hr/> (Last) (First) (Middle) C/O CONMED CORPORATION 525 FRENCH ROAD <hr/> (Street) UTICA NY 13502 <hr/> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 02/25/2015	3. Issuer Name and Ticker or Trading Symbol <u>CONMED CORP [CNMD]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input type="checkbox"/> 10% Owner <input type="checkbox"/> <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) VP Corp. Treasurer	5. If Amendment, Date of Original Filed (Month/Day/Year) <hr/> 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
401 (K) Plan	1,231.172	I	401 (K) Plan ⁽¹⁾
Common Stock	10,531	D	

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Rsus (restricted Stock Units)	(2)	06/01/2020	Common Stock	800	0	D	
Rsus (restricted Stock Units)	(3)	06/01/2020	Common Stock	1,760	0	D	
Rsus (restricted Stock Units)	(2)	06/01/2021	Common Stock	1,600	0	D	
Rsus (restricted Stock Units)	(2)	06/01/2022	Common Stock	2,400	0	D	
Rsus (restricted Stock Units)	(2)	06/01/2023	Common Stock	3,200	0	D	
Rsus (restricted Stock Units)	(2)	06/01/2024	Common Stock	2,600	0	D	
Sars (Stock Appreciation Rights)	(4)	05/17/2017	Common Stock	2,500	29.92	D	
Sars (Stock Appreciation Rights)	(4)	06/01/2018	Common Stock	2,500	26.69	D	
Sars (Stock Appreciation Rights)	(5)	06/01/2019	Common Stock	2,000	16.46	D	
Sars (Stock Appreciation Rights)	(5)	06/01/2020	Common Stock	10,000	19.26	D	
Sars (Stock Appreciation Rights)	(5)	06/01/2021	Common Stock	10,000	27.63	D	
Sars (Stock Appreciation Rights)	(5)	06/01/2022	Common Stock	10,000	26.09	D	
Sars (Stock Appreciation Rights)	(5)	06/01/2023	Common Stock	10,000	32.93	D	
Sars (Stock Appreciation Rights)	(5)	06/01/2024	Common Stock	6,500	44.9	D	

Explanation of Responses:

1. The 1,231.172 represent shares equivalent in a Company stock fund in the 401 (K) Plan.

2. Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock, par value \$0.01 per share of ConMed Corporation (the "Company") and will be subject to the terms and conditions of the Company's 1999 Amended and Restated Long-Term Incentive Plan, with the RSUs generally vesting over a five year period with the first 20% of the RSUs vesting one year after the grant date.

3. Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock, par value \$0.01 per share of ConMed Corporation (the "Company") and will be subject to the terms and conditions of the Company's 1999 Amended and Restated Long-Term Incentive Plan, with the RSUs vesting over a seven year period with 14% of the RSUs vesting in the first through the fifth year after the grant date and 15% vesting in the sixth and seventh year.

4. The stock appreciation rights ("SARs") were granted under the Company's 2006 Stock Incentive Plan and generally vest in equal amounts over a five year period.

5. The stock appreciation rights ("SARs") were granted under the Company's 1999 Amended and Restated Long-Term Incentive Plan and generally vest in equal amounts over a five year period.

/s/ Daniel S. Jonas for Terence

M. Berge by Power of
Attorney

03/05/2015

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.